SG11201403933UA - Heterocyclic amide derivatives as p2x7 receptor antagonists - Google Patents

Heterocyclic amide derivatives as p2x7 receptor antagonists

Info

Publication number
SG11201403933UA
SG11201403933UA SG11201403933UA SG11201403933UA SG11201403933UA SG 11201403933U A SG11201403933U A SG 11201403933UA SG 11201403933U A SG11201403933U A SG 11201403933UA SG 11201403933U A SG11201403933U A SG 11201403933UA SG 11201403933U A SG11201403933U A SG 11201403933UA
Authority
SG
Singapore
Prior art keywords
receptor antagonists
amide derivatives
heterocyclic amide
heterocyclic
derivatives
Prior art date
Application number
SG11201403933UA
Inventor
Kurt Hilpert
Francis Hubler
Thierry Kimmerlin
Dorte Renneberg
Simon Stamm
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of SG11201403933UA publication Critical patent/SG11201403933UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201403933UA 2012-01-20 2013-01-18 Heterocyclic amide derivatives as p2x7 receptor antagonists SG11201403933UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2012050282 2012-01-20
PCT/IB2013/050479 WO2013108227A1 (en) 2012-01-20 2013-01-18 Heterocyclic amide derivatives as p2x7 receptor antagonists

Publications (1)

Publication Number Publication Date
SG11201403933UA true SG11201403933UA (en) 2014-08-28

Family

ID=47757670

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201403933UA SG11201403933UA (en) 2012-01-20 2013-01-18 Heterocyclic amide derivatives as p2x7 receptor antagonists

Country Status (23)

Country Link
US (1) US9409917B2 (en)
EP (1) EP2804865B1 (en)
JP (1) JP6111268B2 (en)
KR (1) KR102033190B1 (en)
CN (1) CN104066737B (en)
AR (1) AR089753A1 (en)
AU (1) AU2013210682B2 (en)
BR (1) BR112014017735B1 (en)
CA (1) CA2863228C (en)
CL (1) CL2014001772A1 (en)
EA (1) EA024204B1 (en)
ES (1) ES2563189T3 (en)
HK (1) HK1203932A1 (en)
IL (1) IL233662A0 (en)
MA (1) MA35893B1 (en)
MX (1) MX336247B (en)
NZ (1) NZ628910A (en)
PH (1) PH12014501415A1 (en)
PL (1) PL2804865T3 (en)
SG (1) SG11201403933UA (en)
TW (1) TWI576347B (en)
WO (1) WO2013108227A1 (en)
ZA (1) ZA201406085B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687860B (en) 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 As P2X7The heterocyclic amide derivative of receptor antagonist
JP6295269B2 (en) 2012-12-12 2018-03-14 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Indole carboxamide derivatives as P2X7 receptor antagonists
US9556117B2 (en) 2012-12-18 2017-01-31 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as P2X7 receptor antagonists
ES2616883T3 (en) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
WO2014115072A1 (en) 2013-01-22 2014-07-31 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
ES2813424T3 (en) * 2014-03-26 2021-03-23 Childrens Medical Ct Corp Celastrol derivatives for the treatment of obesity
AU2018235561B2 (en) 2017-03-13 2020-06-18 Asahi Kasei Pharma Corporation Tetrahydroquinoline derivatives as P2X7 receptor antagonists
DK3740481T3 (en) 2018-01-19 2024-07-08 Cytokinetics Inc Dihydrobenzofuran and indene analogues as cardiac sarcoma inhibitors
WO2020005887A1 (en) 2018-06-26 2020-01-02 Cytokinetics, Inc. Cardiac sarcomere inhibitors
AU2022229390A1 (en) 2021-03-04 2023-09-21 Cytokinetics, Inc. Cardiac sarcomere inhibitors

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0009651A (en) 1999-04-09 2002-01-08 Astrazeneca Ab Compound, process for preparing a compound, pharmaceutical composition, use of a compound, and method for treating rheumatoid arthritis and an obstructive airway disease
SE9904505D0 (en) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
PA8557501A1 (en) 2001-11-12 2003-06-30 Pfizer Prod Inc BENZAMIDA, HETEROARILAMIDA AND INVESTED AMIDAS
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (en) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (en) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
PA8591801A1 (en) 2002-12-31 2004-07-26 Pfizer Prod Inc BENZAMID INHIBITORS OF THE P2X7 RECEIVER.
BR0317844A (en) 2002-12-31 2005-12-06 Pfizer Prod Inc P2x7 receptor benzamide inhibitors
SE0300480D0 (en) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
JP4731468B2 (en) 2003-05-12 2011-07-27 ファイザー・プロダクツ・インク Benzamide inhibitor of P2X7 receptor
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (en) 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
EP1683043A1 (en) * 2003-10-30 2006-07-26 Koninklijke Philips Electronics N.V. Method of predicting input
JP2007535553A (en) * 2004-04-29 2007-12-06 アボット・ラボラトリーズ Amino-tetrazole analogs and methods of use
SA05260265A (en) 2004-08-30 2005-12-03 استرازينيكا ايه بي Novel compounds
SE0402925D0 (en) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US20080146612A1 (en) 2005-01-27 2008-06-19 Astrazeneca Ab Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor
US7238702B2 (en) 2005-02-10 2007-07-03 Bristol-Myers Squibb Company Dihydroquinazolinones as 5HT modulators
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2007055374A1 (en) * 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for osteoporosis
TWI464148B (en) 2006-03-16 2014-12-11 Evotec Us Inc Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109154A2 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
CA2645551C (en) 2006-03-16 2016-06-28 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109201A2 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109182A2 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
JP5306987B2 (en) 2006-03-16 2013-10-02 エボテック （ユーエス） インコーポレイテッド Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
GB0611154D0 (en) 2006-06-06 2006-07-19 Glaxo Group Ltd Novel receptor antagonists and their methods of use
WO2007141267A1 (en) 2006-06-06 2007-12-13 Glaxo Group Limited N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration
EP2049478B1 (en) 2006-07-06 2012-05-30 Glaxo Group Limited Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
EA201300152A1 (en) 2006-11-27 2013-07-30 Х. Лундбекк А/С HETEROARILAMID DERIVATIVES
TW200838516A (en) 2007-01-31 2008-10-01 Merck & Co Inc Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
DK2124562T3 (en) 2007-03-09 2016-08-01 Second Genome Inc BICYCLOHETEROARYLFORBINDELSER AS P2X7 modulators and uses thereof
KR20090122396A (en) 2007-03-22 2009-11-27 아스트라제네카 아베 Quinoline derivatives for the treatment of inflammatory diseases
GB0705882D0 (en) 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
JP2010522711A (en) 2007-03-28 2010-07-08 グラクソ グループ リミテッド Piperidinone carboxamide derivatives as P2X7 modulators
EP2139875A2 (en) 2007-03-29 2010-01-06 Glaxo Group Limited Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators
CA2682649A1 (en) 2007-04-03 2008-10-09 Glaxo Group Limited Imidazolidine carboxamide derivatives as p2x7 modulators
KR20090130109A (en) 2007-04-10 2009-12-17 하. 룬트벡 아크티에 셀스카브 Heteroaryl amide analogues as p2x7 antagonists
US20100056595A1 (en) 2007-04-11 2010-03-04 Glaxo Group Limited Pyrazole Derivatives as P2X7 Modulators
WO2008138876A1 (en) 2007-05-10 2008-11-20 Glaxo Group Limited Pyrazole derivatives as p2x7 modulators
RS54303B1 (en) 2007-07-19 2016-02-29 Lundbeck, H., A/S 5-membered heterocyclic amides and related compounds
WO2009023623A1 (en) * 2007-08-10 2009-02-19 H, Lundbeck A/S Heteroaryl amide analogues
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
GB0724258D0 (en) 2007-12-12 2008-01-30 Glaxo Group Ltd Novel combinations
WO2009074518A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations of prolinamide p2x7 modulators with further therapeutic agents
GB0724625D0 (en) 2007-12-18 2008-01-30 Glaxo Group Ltd Novel compounds
CN101945655A (en) 2007-12-18 2011-01-12 葛兰素集团有限公司 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
DK2105164T3 (en) * 2008-03-25 2011-03-21 Affectis Pharmaceuticals Ag New P2X7R antagonists and their use
CA2722035C (en) 2008-04-22 2016-10-11 Janssen Pharmaceutica Nv Quinoline or isoquinoline substituted p2x7 antagonists
AU2010237302A1 (en) 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
US20120157494A1 (en) 2010-12-16 2012-06-21 Harris Iii Ralph New Isoindolyl compounds
JP2014513671A (en) 2011-02-22 2014-06-05 アクテリオン ファーマシューティカルズ リミテッド Benzamide derivatives as P2X7 receptor antagonists
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CN103687860B (en) 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 As P2X7The heterocyclic amide derivative of receptor antagonist
JP6295269B2 (en) 2012-12-12 2018-03-14 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Indole carboxamide derivatives as P2X7 receptor antagonists
US9556117B2 (en) 2012-12-18 2017-01-31 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as P2X7 receptor antagonists
ES2616883T3 (en) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
WO2014115072A1 (en) 2013-01-22 2014-07-31 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists

Also Published As

Publication number Publication date
EA201400822A1 (en) 2014-12-30
TWI576347B (en) 2017-04-01
BR112014017735A8 (en) 2017-12-26
CN104066737B (en) 2016-06-08
US20150025075A1 (en) 2015-01-22
JP6111268B2 (en) 2017-04-05
PL2804865T3 (en) 2016-06-30
AU2013210682B2 (en) 2017-05-25
MX336247B (en) 2016-01-13
EP2804865A1 (en) 2014-11-26
CN104066737A (en) 2014-09-24
MA35893B1 (en) 2014-12-01
CA2863228A1 (en) 2013-07-25
US9409917B2 (en) 2016-08-09
AU2013210682A1 (en) 2014-09-11
KR102033190B1 (en) 2019-10-16
NZ628910A (en) 2016-02-26
EP2804865B1 (en) 2015-12-23
BR112014017735A2 (en) 2017-06-27
CA2863228C (en) 2020-07-21
BR112014017735B1 (en) 2022-06-28
ES2563189T3 (en) 2016-03-11
KR20140112567A (en) 2014-09-23
PH12014501415A1 (en) 2014-09-22
TW201333013A (en) 2013-08-16
IL233662A0 (en) 2014-08-31
HK1203932A1 (en) 2015-11-06
MX2014008736A (en) 2014-08-29
AR089753A1 (en) 2014-09-17
CL2014001772A1 (en) 2014-10-17
EA024204B1 (en) 2016-08-31
ZA201406085B (en) 2016-05-25
WO2013108227A1 (en) 2013-07-25
JP2015504086A (en) 2015-02-05

Similar Documents

Publication Publication Date Title
ZA201504974B (en) Indole carboxamide derivatives as p2x7 receptor antagonists
HK1203932A1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists p2x7
AP3862A (en) Novel benzimidazole derivatives as ep4 antagonists
HK1203191A1 (en) P2x4 receptor antagonist p2x4
IL227664A0 (en) Novel heterocyclic derivatives
HK1195901A1 (en) Cyclic amine derivatives as ep4 receptor antagonists ep4
HK1190703A1 (en) Heterocyclic amine derivatives
EP2619204A4 (en) Triazolopyrazinones as p2x7 receptor antagonists
HK1225712A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
HK1199878A1 (en) Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists
HRP20150974T1 (en) 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors
PT2935227T (en) Diazole amides as ccr1 receptor antagonists
HK1187914A1 (en) Pyrrolidine derivatives as nk3 antagonists nk3
EP2846800A4 (en) Heterocyclic cgrp receptor antagonists